The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
Texas MPN Workshop 2022 | Novel targets and combinations being explored in MPNs
In this video, Claire Harrison, MD, DM, FRCP, FRCPath, Guy’s and St Thomas’ NHS Foundation Trust, London, UK, gives an overview of novel targets and combination approaches being explored in myeloproliferative neoplasms (MPNs). Prof. Harrison highlights the promise of novel JAK inhibitors, such as momelotinib, and MDM2 inhibitors, including navtemadlin, and the importance of better understanding how to combine and implement these agents in clinical practice. This interview took place at the third annual Texas MPN Workshop (TMW) 2022, held in San Antonio, TX.
Disclosures
Research funding: Celgene, Constellation, Novartis Advisory role: AbbVie, AOP, BMS, Celgene, CTI, Novartis, Galacteo, Geron, Gilead, Janssen, Keros, Promedior, Roche, Shire, Sierra
